Slc35A1 has been demonstrated to improve effector T cell response, decrease the amount of 2,6-linked sialic acids on the cell surface, and boost the inflow and activity of natural killer (NK) cells, strengthening anti-tumor immunity and slowing tumor progression [29]. This evidence concerns the gene SLC35A1 and neoplasm.